News | March 10, 2026
Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
The first of four planned modules at the new plant is expected to come online by summer 2026
The first of four planned modules at the new plant is expected to come online by summer 2026
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Subscribe To Our Newsletter & Stay Updated
